Few wellness products carry as much legal ambiguity as Holistapet CBD oil, and that ambiguity isn’t accidental. It’s the direct result of federal and state law developing on different timelines, sometimes contradicting each other in ways that leave everyday buyers confused about what’s actually settled. Understanding the layers involved, federal, FDA, and state, clears up most of that confusion fairly quickly.
The starting point is the Agriculture Improvement Act of 2018, better known as the Farm Bill. This legislation removed hemp, defined as cannabis containing no more than 0.3% THC by dry weight, from the Controlled Substances Act. Before that, all cannabis, hemp included, sat in the same federal legal category as marijuana regardless of THC content. The 2014 Farm Bill had opened a narrower door, allowing hemp cultivation strictly under state agricultural pilot programs. It took the 2018 version to fully legalize commercial hemp cultivation and processing nationwide, setting up the legal basis for the CBD oil market that exists today, one that continues to evolve as more states and federal agencies weigh in on the details.
Hemp Farming Since Legalization
Since the 2018 Farm Bill passed, hemp cultivation has expanded across a range of states, with Kentucky, Colorado, and Oregon among the states that built out significant hemp farming infrastructure relatively early, partly due to existing agricultural expertise and, in Colorado’s case, an existing regulatory framework left over from its broader cannabis legalization efforts for adult use. The U.S. Department of Agriculture oversees hemp cultivation licensing at the federal level, while individual states can implement their own additional plans subject to USDA approval, which is part of why the specific cultivation rules a farmer follows can vary somewhat from state to state even under the same underlying federal law.
Where the FDA Actually Stands
Here’s a fact that surprises a lot of people: no CBD product currently holds FDA approval as a general-purpose supplement or over-the-counter product. The one notable exception is Epidiolex, a highly purified, prescription-only CBD formulation approved specifically for treating certain severe forms of epilepsy. That approval doesn’t extend to the broader retail CBD oil market, and the FDA has issued warning letters over the years to companies making unauthorized health claims, particularly those suggesting a product can treat, cure, or prevent a specific disease.
This creates a legal gap worth understanding directly: CBD oil is federally legal to manufacture and sell as a hemp product, but it isn’t FDA-approved as a supplement or drug for general health claims, which shapes what a bottle’s label is legally permitted to say.
State-Level Variation
States haven’t uniformly aligned their own regulations with federal hemp law. A few patterns show up repeatedly:
- Some states require hemp product registration with a state agriculture department before retail sale
- A handful of states impose additional labeling requirements beyond federal minimums, including mandatory QR codes linking to lab results
- Certain states have set their own THC threshold enforcement practices, occasionally stricter in practice than the federal 0.3% baseline
- A small number of jurisdictions have implemented age-verification requirements at the point of sale, even though CBD itself is not federally age-restricted
Checking a specific state’s current hemp regulations is a reasonable step before purchasing, particularly in states that have historically taken a more cautious regulatory stance toward hemp-derived products generally. This kind of variation isn’t unique to CBD; it mirrors how many other product categories, from lottery tickets to certain over-the-counter medications, are handled differently depending on which state a buyer happens to live in.
Marijuana-Derived CBD Is a Separate Legal Category
CBD extracted from marijuana plants, rather than hemp, remains federally illegal regardless of its actual CBD content, because marijuana itself is still classified as Schedule I under federal law. This holds true even in states that have legalized recreational or medical marijuana, since state legalization doesn’t override federal scheduling; it simply means the state has chosen not to enforce its own laws against it. A dispensary-sourced product in a legal marijuana state and a hemp-derived product purchased online exist in genuinely different legal categories, something labels don’t always make obvious at a glance.
The DEA’s Narrower Role Since 2018
Before the 2018 Farm Bill, the Drug Enforcement Administration treated all cannabis-derived products, hemp included, under the same Schedule I framework. That changed once hemp was removed from the Controlled Substances Act, shrinking the DEA’s jurisdiction considerably for compliant, low-THC hemp products. The agency retains enforcement authority over products exceeding the 0.3% THC threshold, since those fall back into federally controlled territory regardless of marketing language.
Veteran and Federal Employee Considerations
A specific group worth mentioning separately: federal employees, military service members, and certain federally regulated transportation workers (commercial pilots, truck drivers subject to DOT testing) operate under policies that can treat any CBD use, even fully compliant hemp-derived products, more strictly than general state or federal law requires. The Department of Veterans Affairs, for instance, has issued guidance advising veterans to discuss CBD use with their VA provider given the trace THC risk in some formulations and the department’s own testing policies. Anyone in a federally regulated position is generally better served checking employer-specific policy directly rather than assuming general federal legality automatically extends to workplace rules.
How Enforcement Actually Plays Out
FDA enforcement against CBD companies has focused mainly on marketing language rather than shutting down the industry outright. Warning letters typically ask a company to remove specific disease-treatment claims, statements suggesting a product can cure cancer or treat serious illness, rather than pulling the underlying product from shelves entirely. This is part of why the CBD oil market has continued to grow steadily even without a formal FDA approval pathway: the enforcement mechanism targets specific claims, not the hemp-derived product category as a whole.
A Brief Timeline
The regulatory picture developed over decades, not overnight. The 1970 Controlled Substances Act originally classified all cannabis, hemp included, as Schedule I, which effectively ended commercial hemp farming in the United States for decades. The 2014 Farm Bill permitted limited hemp cultivation strictly through state-run agricultural pilot programs, mostly research-focused rather than commercial. The 2018 Farm Bill removed hemp from the Controlled Substances Act entirely, establishing the legal basis for the commercial market that exists today. None of these steps included a corresponding FDA approval process for CBD as a general supplement, which explains why that particular regulatory gap has persisted even as cultivation and retail sales became broadly legal.
Traveling and Shipping Considerations
Federally compliant hemp CBD oil generally ships across state lines without violating federal transport law, part of why online, direct-to-consumer sales dominate this market compared to more geographically restricted product categories. International travel is a different question entirely. Many countries maintain far stricter cannabis laws than U.S. federal law, and carrying any hemp-derived product across an international border, even one legal domestically, can create complications that a purely domestic purchase wouldn’t.
Insurance and Reimbursement
Because CBD oil is sold as a supplement rather than an FDA-approved medication, health insurance plans and HSA/FSA accounts generally don’t cover it the way they would a prescribed medication, though this varies somewhat by specific plan and by whether a state has passed any legislation addressing the point directly. Some FSA administrators have begun accepting CBD purchases with appropriate documentation in recent years as rules around eligible expenses have loosened slightly, though this remains inconsistent across providers and isn’t something to assume without checking a specific plan’s current guidelines first.
Retail Patterns Shaped by This Legal Landscape
The legal ambiguity discussed throughout this article has shaped retail availability in a fairly visible way. Larger national retail chains, particularly ones operating across states with differing local ordinances, have generally been more cautious about stocking CBD products on physical shelves than the federal legal framework alone would suggest is necessary. This caution traces back to the lingering FDA supplement enforcement ambiguity rather than any actual federal prohibition, and it’s a meaningful part of why online, direct-to-consumer retail has grown faster than brick-and-mortar availability specifically within this product category, even as hemp cultivation and sales became broadly legal nationwide.
What This Means Practically for Buyers
None of this legal complexity needs to be memorized in full to shop responsibly. Checking that a product is explicitly hemp-derived, confirming the THC content sits at or below 0.3% via the COA, and being aware that state rules can vary covers most of the practical ground an everyday buyer actually needs. The deeper regulatory history matters more for understanding why the market looks the way it does, uneven retail availability, cautious labeling language, inconsistent state rules, than for any single purchasing decision.
Final Thoughts
CBD oil sits in a specific legal position: federally legal to manufacture and sell under the Farm Bill’s hemp provisions, without FDA approval for general supplement or health claims, and subject to a patchwork of state-level rules that continue to shift as more states clarify their own regulatory stance over the coming years.
